FY2024 EPS Estimates for Repligen Lifted by William Blair

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for shares of Repligen in a research report issued on Wednesday, December 11th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $1.58 per share for the year, up from their previous forecast of $1.44. The consensus estimate for Repligen’s current full-year earnings is $1.52 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.45 EPS, Q1 2025 earnings at $0.38 EPS, Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.45 EPS and Q4 2025 earnings at $0.50 EPS.

A number of other equities analysts have also recently weighed in on RGEN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Trading Up 0.3 %

Shares of RGEN opened at $156.41 on Friday. The firm has a 50-day moving average price of $142.66 and a 200 day moving average price of $141.66. The firm has a market capitalization of $8.76 billion, a P/E ratio of -422.72, a P/E/G ratio of 4.67 and a beta of 0.96. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the business earned $0.23 EPS. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently modified their holdings of RGEN. Andra AP fonden purchased a new stake in Repligen in the 2nd quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in Repligen in the second quarter valued at about $33,000. UMB Bank n.a. lifted its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. lifted its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV purchased a new position in Repligen in the third quarter valued at about $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.